Syntekabio announced that it will participate in the 2025 JP Morgan Healthcare Conference and Biotech Showcase held in San Francisco on Jan. 13 (local time) to showcase its language model software-as-a-service (SaaS) for global pharmaceutical companies and biotech firms. According to the company, this is a fusion AI platform that can generate valid substances targeting diseases in an infinite loop based on bio big data, including 200 million protein structures predicted by Google AlphaFold, all known three-dimensional structure bank data, and a library of over 10 billion compounds. CEO Jeong Jong-seon noted, "The newly prepared SaaS modularizes the platform service so that client companies can use only the services they want, lowering the entry barrier for AI drug platform services and increasing accessibility, which is expected to lead to more adoption attempts by client companies." The company stated that its U.S. subsidiary has already made 35 pre-reserved partnerships with pharmaceutical companies.
DXVX will participate in the JP Morgan Healthcare Conference and Biotech Showcase to discuss partnering with global corporations. At this event, it will introduce the world’s only room-temperature, ultra-long-term storage mRNA vaccine platform, developed jointly with professors from Pohang University of Science and Technology, as part of the first ARPA-H project. The company plans to focus on discussions regarding the sublicensing business for the platform through meetings with global pharmaceutical companies. It will also actively promote its next-generation sequencing (NGS) universal diagnostic innovation platform through global partnering meetings.
The electronic medicine platform company Y-Brain is developing a wearable robot for patients with quadriplegia and an associated electric wheelchair, becoming the first in the country to do so. Y-Brain announced on Jan. 13 that it has been selected as a collaborative research and development institute for the Global Industrial Technology Cooperation Center project, which is organized by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology (KIAT). This project involves developing a wearable robot for the rehabilitation of quadriplegic patients based on minimally invasive brain-computer interface (BCI) technology to measure brain nerve signals, conducted jointly with the Korea Institute of Science and Technology, Pusan National University, ETH Zurich, and the French National Centre for Scientific Research.
ENCell announced on Jan. 13 that it has completed the development of the production process for adenovirus-associated virus (AAV) in collaboration with the biotech company Sartorius Korea. AAV is a gene delivery viral vector system that plays a key role in gene therapy due to its low immunogenicity and integration into the genome. For large-scale AAV production, building technology and efficient production systems is crucial. ENCell possesses its own experience in developing AAV production technology, and Sartorius Korea has expertise in automation and optimization in large-scale production processes; both companies expect this collaboration to bring a turning point in the development and production of gene therapies.
Verismo Therapeutics, a subsidiary of HLB Innovation, announced on Jan. 13 that it has completed the first patient administration of its next-generation chimeric antigen receptor T-cell (CAR-T) therapy 'SynKIR-310,' which is in development for the treatment of blood cancer. The administration was conducted at the Colorado Blood Cancer Institute (CBCI) of the Sarah Cannon Research Institute (SCRI) in the U.S. This clinical trial is designed as a single-dose, multicenter, open-label study involving up to 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, either previously treated with or without CAR-T therapy. The study aims to evaluate the efficacy of SynKIR-310 in B-cell non-Hodgkin lymphoma subtypes such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), assessing safety, tolerability, and preliminary efficacy while determining the recommended dose for phase 2 clinical trials.
Dong-A ST and Meju announced that they showcased their real-time patient monitoring platform 'HiCardiPlus' and 'HiCardiPlus H100', which has obtained certification from the U.S. Food and Drug Administration (FDA), at the CES 2025 held in Las Vegas from Jan. 7 to 10. HiCardi is a mobile biosignal monitoring system that allows for real-time monitoring of multiple patients' electrocardiogram (ECG), heart rate, body surface temperature, and respiration anytime and anywhere using wearable patches and smartphones. The lightweight wearable patch alleviates the discomfort experienced by patients and medical staff with traditional ECG monitors.
Chong Kun Dang signed a sponsorship agreement with professional golfer Kim Min-kyu, who is active in the Korea Professional Golf (KPGA) Tour and the DP World Tour (DPWT), and held a ceremony on Jan. 13. Sponsorship agreements with national representative Park Jeong-hoon for 2024 and professional golfer Kang Jeong-hyun from the Korea Ladies Professional Golf (KLPGA) have also been processed. Through this agreement, the players will wear hats and tops featuring Chong Kun Dang's corporate logo and the logos of its probiotics product 'LactoFit' and premium vitamins 'I'm Vita' in all upcoming tournaments. The company stated, "We will actively support all three players to grow into world-class athletes and contribute to the revitalization of the golf industry."
GC Green Cross announced on Jan. 13 that it has released a renewed version of its over-the-counter medicine 'Green Nose Plus Soft Capsule,' which is effective in reducing nasal and bronchial secretions. The new version features the addition of anhydrous caffeine, resulting in fewer drowsiness side effects compared to the previous product, and it acts faster to alleviate cold symptoms. The light green oval soft capsule formulation is to be taken at a dosage of one capsule three times a day after meals for those aged 15 and older.
DAEWON announced that it will launch a new version of its antipyretic and analgesic anti-inflammatory drug 'Peluvi Tablets' called 'Peluvi S Tablets.' Peluvi S Tablets enhance solubility and reduce gastrointestinal distress effects. Compared to Peluvi Tablets, the area of gastric mucosal damage was reduced by more than half, proving the effect of improving gastrointestinal side effects. Peluvi Tablets, containing the active ingredient Peluvidine, were an indigenous new drug launched in 2007, which began as an analgesic and anti-inflammatory medication and expanded its treatment range to include antipyretic indications for acute upper respiratory infections in 2017.
Kwangdong Pharmaceutical unveiled a new TV advertisement for 'Kwangdong Gyeong Ok Go,' featuring actor Cho Woo-jin. Kwangdong Gyeong Ok Go is manufactured by combining four herbal materials—raw Rehmannia juice, ginseng, Poria powder, and honey—in optimal ratios, undergoing a 120-hour steaming process in a GMP-certified facility, and can be purchased as an over-the-counter medicine at pharmacies. It is expected to provide revitalizing effects for consumers with various health concerns, such as office workers suffering from chronic fatigue, patients needing recovery after illness, and middle-aged individuals experiencing menopausal disorders.
The Jasaeng Oriental Medicine Hospital's Spine and Joint Research Institute announced on Jan. 13 that it is recruiting participants for a clinical study on patients suffering from moderate to severe low back pain or pain and numbness occurring in the lower back associated with lumbar disc herniation (lumbar intervertebral disc herniation). The recruitment criteria include: ▲ patients complaining of moderate to severe low back pain or radicular pain; ▲ patients for whom radicular pain has lasted for more than one month; and ▲ patients aged 19 to 69 who can visit the hospital during the study period. The study period includes an 8-week treatment period followed by a total of 3 years of follow-up observation. The research will be conducted at four locations, including the Jasaeng Oriental Medicine Hospital in Gangnam, Seoul, Daejeon Jasaeng Oriental Medicine Hospital, Bucheon Jasaeng Oriental Medicine Hospital, and Haeundae Jasaeng Oriental Medicine Hospital. For participation inquiries, contact the representative number of the Jasaeng Oriental Medicine Hospital.